Pembrolizumab with enzalutamide for treating
metastatic castration-resistant prostate cancer

Pembrolizumab in addition to enzalutamide is in clinical development for patients with prostate
cancer which has spread from its original site (metastatic), is untreatable via testosterone
suppression therapy (castration resistant), and who are either abiraterone acetate naïve or have
progressed on abiraterone acetate. Prostate cancer is a cancer of the prostate gland (a small organ
in a man’s pelvis) and is the most common cancer in men in the UK. The symptoms may vary
depending on the stage of cancer but can include pain, tiredness, and problems emptying the
bladder and the bowels. The castration-resistant form of metastatic prostate cancer is particularly
dangerous and leads to a very poor prognosis hence additional treatment options are needed.